Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-06-09
2010-11-02
Zeman, Robert A (Department: 1645)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S325000
Reexamination Certificate
active
07825233
ABSTRACT:
Nucleic acid molecules that comprise modified open reading frames providing increased expression of the encoded active BoNT/E in a heterologous cell, expression constructs and cells comprising such nucleic acid molecules and methods useful for expressing the encoding active BoNT/E from such nucleic acid molecules, expression constructs and cells.
REFERENCES:
patent: 6114148 (2000-09-01), Seed et al.
patent: 6121014 (2000-09-01), Koziel et al.
patent: 6153377 (2000-11-01), Devare et al.
patent: 6214602 (2001-04-01), Zdanovsky
patent: 6218188 (2001-04-01), Cardineau et al.
patent: 6277622 (2001-08-01), Weiss
patent: 6319505 (2001-11-01), Aoki et al.
patent: 6399857 (2002-06-01), Kloti
patent: 6538127 (2003-03-01), Devare et al.
patent: 6733994 (2004-05-01), Weiner et al.
patent: 7037680 (2006-05-01), Smith et al.
patent: 2003/0009025 (2003-01-01), Smith et al.
patent: 2004/0092009 (2004-05-01), Draghia-Akli et al.
patent: WO 00/12728 (2000-03-01), None
patent: WO 00/67700 (2000-11-01), None
patent: WO 02/36758 (2002-05-01), None
patent: WO 02/089834 (2002-11-01), None
Bork (Genome Research, 2000,10:398-400).
Bowie et al (Science, 1990, 257:1306-1310).
Smith et al, “Light Chain of Botulinum a Neurotoxin Expressed as an Inclusion Body from a Synthetic Gene is Catalytically and Functionally Active”, 19 J. Protein Chem. 475-487, (2000).
Byrne et al, “Fermentation, Purification, and Efficacy of a Recombinant Vaccine Candidate Against Botulinum Neurotoxin Type F from Pichia pastoris”, 18 Protein Expr. Purif. 327-337, (2000).
Karlin et al, “Codon usages in different gene classes of theEscherichia coligenome”, Molecular Microbilogy (1998) 29(6), 1341-1355.
Lin et al, The use of synthetic genes for the expression of ciliate proteins in heterologous systems, Gene 288 (2002) 85-94.
Madzak et al, “Heterologous protein expression and secretion in the non-conventional yeast Yarowia lipolytica: a review”, Journal of Biotechnology 109 (2004) 63-81.
Makoff et al.,Expression of Tetanus Toxin Fragment C in E. coli: High Level Expression by Removing Rare Codons, 17 Nucleic Acids Res. 10191-10202, (1989).
Pellizzari et al, “Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses”, BiolSci Feb. 28, 1999; 354 (1381):259-268.
Potter et al.,Production and Purification of the Heavy-Chain Fragment C of Botulinum Neurotoxin, Serotype A, Expressed in the Methylotrophic Yeast Pichia pastoris, 19 Protein Expr. Purif. 393-402, (2000).
Potter et al.,Production and Purification of the Heavy-Chain Fragment C of Botulinum Neurotoxin, Serotype B, Expressed in the Methylotrophic Yeast Pichia pastoris, 13 Protein Expr. Purif. 357-365, (1998).
Leonard A. Smith,Development of Recombinant Vaccines for Botulinum Neurotoxin, 36 TOXICON 1539-1548, (1998).
Chen et al, “Sequencing the Botulinum Neurotoxin Gene and Related Genes in Clostridium botulinum Type E Strains Reveals . . . ” Journal of Bacteriology, vol. 189, No. 23, p. 8643-8650, Dec. 2007.
Aoki Kei Roger
Fernandez-Salas Ester G.
Gilmore Marcella A.
Li Shengwen
Miller Ronald G.
Allergan Inc.
Condino Debra
Stathakis Dean G.
Zeman Robert A
LandOfFree
Optimizing expression of active Botulinum Toxin type E does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Optimizing expression of active Botulinum Toxin type E, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Optimizing expression of active Botulinum Toxin type E will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4242367